OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Ignacio Melero, Miguel F. Sanmamed, Javier Glez‐Vaz, et al.
Cancer Discovery (2022) Vol. 13, Iss. 3, pp. 552-569
Closed Access | Times Cited: 42
Ignacio Melero, Miguel F. Sanmamed, Javier Glez‐Vaz, et al.
Cancer Discovery (2022) Vol. 13, Iss. 3, pp. 552-569
Closed Access | Times Cited: 42
Showing 1-25 of 42 citing articles:
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Antonio Tapia‐Galisteo, Luis Álvarez‐Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 56
Antonio Tapia‐Galisteo, Luis Álvarez‐Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 56
Cross-priming in cancer immunology and immunotherapy
Carlos Luri‐Rey, Álvaro Teijeira, Stefanie K. Wculek, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 3
Carlos Luri‐Rey, Álvaro Teijeira, Stefanie K. Wculek, et al.
Nature reviews. Cancer (2025)
Closed Access | Times Cited: 3
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Nikhil I. Khushalani, Patrick A. Ott, Robert L. Ferris, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007364-e007364
Open Access | Times Cited: 12
Nikhil I. Khushalani, Patrick A. Ott, Robert L. Ferris, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e007364-e007364
Open Access | Times Cited: 12
CD8+ T cell priming that is required for curative intratumorally anchored anti-4-1BB immunotherapy is constrained by Tregs
Joseph R. Palmeri, Brianna M. Lax, Joshua M. Peters, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Joseph R. Palmeri, Brianna M. Lax, Joshua M. Peters, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 9
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies
Ana Paula Carneiro, Amanda Hahn, Peter Ellmark, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010113-e010113
Open Access | Times Cited: 1
Ana Paula Carneiro, Amanda Hahn, Peter Ellmark, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010113-e010113
Open Access | Times Cited: 1
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models
Eneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e009852-e009852
Open Access | Times Cited: 1
Eneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e009852-e009852
Open Access | Times Cited: 1
Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
Guizhong Liu, Peter Luo
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Guizhong Liu, Peter Luo
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Recent advances in immunotherapy in cancer treatment
Ayyub Patel
Cellular and Molecular Biology (2024) Vol. 70, Iss. 5, pp. 89-99
Open Access | Times Cited: 5
Ayyub Patel
Cellular and Molecular Biology (2024) Vol. 70, Iss. 5, pp. 89-99
Open Access | Times Cited: 5
Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity
Qian‐Ni Ye, Long Zhu, Jie Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Qian‐Ni Ye, Long Zhu, Jie Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer
Xiang Gao, Ling Yi, Chang Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Xiang Gao, Ling Yi, Chang Jiang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications
Shahram Salek‐Ardakani, Dirk M. Zajonc, Michael Croft
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Shahram Salek‐Ardakani, Dirk M. Zajonc, Michael Croft
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
The multifaceted role of PCSK9 in cancer pathogenesis, tumor immunity, and immunotherapy
Chou‐Yi Hsu, Mustafa Nasrat Abdulrahim, Mohammed Ahmed Mustafa, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access | Times Cited: 4
Chou‐Yi Hsu, Mustafa Nasrat Abdulrahim, Mohammed Ahmed Mustafa, et al.
Medical Oncology (2024) Vol. 41, Iss. 8
Closed Access | Times Cited: 4
Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets
Yutong Zhao, C.M. Qin, Lin Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189183-189183
Closed Access | Times Cited: 4
Yutong Zhao, C.M. Qin, Lin Chen, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189183-189183
Closed Access | Times Cited: 4
Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation
Oana Hangiu, Rocío Navarro, Susana Frago, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Oana Hangiu, Rocío Navarro, Susana Frago, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity
Da-yan Zhang, Zhihua Zhang, Wenting Liu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Da-yan Zhang, Zhihua Zhang, Wenting Liu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access
The potential impact of RNA splicing abnormalities on immune regulation in endometrial cancer
M D Cao, Jiayu Yan, Yan Ding, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
M D Cao, Jiayu Yan, Yan Ding, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Characterization of alternative sPD-1 isoforms reveals that ECD sPD-1 signature predicts an efficient antitumor response
Ping Hou, Li Hu, Junrong Zhang, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Ping Hou, Li Hu, Junrong Zhang, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
New insights into cancer immune checkpoints landscape from single-cell RNA sequencing
Qian Wang, Jiahui He, Tianyu Lei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 3, pp. 189298-189298
Closed Access
Qian Wang, Jiahui He, Tianyu Lei, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 3, pp. 189298-189298
Closed Access
TNFR2/CCR8 bispecific antibody enhances antitumor activity through depleting Ti-Tregs and boosting effector CD8 + T cell function
Ran Wang, Jiefang Xu, Shipeng Cheng, et al.
OncoImmunology (2025) Vol. 14, Iss. 1
Open Access
Ran Wang, Jiefang Xu, Shipeng Cheng, et al.
OncoImmunology (2025) Vol. 14, Iss. 1
Open Access
Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists
George Fromm, Suresh de Silva, Taylor H. Schreiber
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
George Fromm, Suresh de Silva, Taylor H. Schreiber
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma
Yuxiang Ma, Fan Luo, Yang Zhang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101414-101414
Open Access | Times Cited: 3
Yuxiang Ma, Fan Luo, Yang Zhang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101414-101414
Open Access | Times Cited: 3
Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
Seung Hyuck Jeon, Gihoon You, Junsik Park, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4155-4166
Closed Access | Times Cited: 3
Seung Hyuck Jeon, Gihoon You, Junsik Park, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 18, pp. 4155-4166
Closed Access | Times Cited: 3
A Humanized Anti-B7H3×4-1BB Bispecific Antibody Exerts Potent Antitumor Effects through the Activation of Innate and Adaptive Immunity
Feng‐Rong Wang, Qun Zhao, Wenting Liu, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 749, pp. 151347-151347
Closed Access
Feng‐Rong Wang, Qun Zhao, Wenting Liu, et al.
Biochemical and Biophysical Research Communications (2025) Vol. 749, pp. 151347-151347
Closed Access
